Russia’s vaccine against covid-19 infection has reported 95 per cent efficacy in second interim analysis, the developers said.
Sputnik V, developed by Gamaleya Institute and RDIF(Russian Direct Investment Fund), is two dose vaccine and will be priced under $20 with each dose costing $10.
The vaccine may be available for public use by February 2021 if everything goes as scheduled.
The Russian Direct Investment Fund (RDIF), second interim analysis of clinical trial data showed a 91.4% efficacy for the Sputnik V vaccine on day 28 after the first dose while the vaccine efficacy is over 95% 42 days after the first dose, the statement issued by the company said.
More than 22,000 volunteers were vaccinated with the first dose while 19,000 volunteers were given first and second doses. The results were proven effective with unexpected adverse events during the trials, it added.
“Gamaleya Center has developed one of the most efficient vaccines against coronavirus in the world with an efficacy rate of more than 90 per cent and a price that is two times lower than that of other vaccines with similar efficacy rate,” Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF) said in a statement.
Meanwhile, in India, the vaccine is yet to undergo late-stage trials. RDIF have collaborated Hyderabad-based Dr Reddy’s to produce the vaccine candidate in India.
As per the statement released by the developers, the first batch of the vaccines will be released in January 2021 based on the existing partnerships with foreign manufacturers.
“There are two forms of the vaccine, one of which requires -18°C (liquid) and must be transported in special refrigerators. Second form is lyophilised(freeze-dry) and can be stored at + 2 to – 8°C. We expect that the freeze-dry version will be supploed in large quantities to many countries to many countries including India in February,” TOI quoted a spokesperson as saying.
As per the existing agreement, RDIF will supply 100 million doses of the vaccine to Dr Reddy in India.